![]() |
![]() |
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26Z,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-2-propanyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4- 23,27-EPOXY-3H-PYRIDO(2,1-C)(1,4)OXAAZACYCLOHENTRIACONTINE 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1S)-2-[(1S,3R,4R)-4-hydroxy -3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-, (3S,6R,7E,9R,10R,12R,14S,15E,17Z,19E,21S,23S,26R,27R,34aS)- AY 22989 azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone EINECS 262-640-9 MFCD00867594 NSC-226080 RAPA Rapamicin RAPAMUNE RAPAMYCIN, STREPTOMYCES HYGROSCOPICUS RPM sila9268a Sirolimus
Poison by intraperitoneal route. Moderately toxic by ingestion. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Hazard Codes:?Xi
Risk Statements: 36/38?
R36/38:Irritating to eyes and skin.
Safety Statements: 22-24/25-37/39-26?
S22:Do not breathe dust.?
S24/25:Avoid contact with skin and eyes.?
S37/39:Wear suitable gloves and eye/face protection.?
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
RTECS of Rapamycin (CAS NO.53123-88-9): VE6250000
? Rapamycin (CAS NO.53123-88-9), its Synonyms are 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone, 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-(3-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-, (3S-
(3R*S*1R*,3S*,4S*)),6S*,7E,9S*,10S*,12S*,14R*,15E,17E,19E,21R*,23R*,26S*,27S*,34aR*))- ; Sirolimus ; Rapammune ; Rapamune . It is white to off-white solid.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 597mg/kg (597mg/kg) | ? | Journal of Antibiotics. Vol. 31, Pg. 539, 1978. |
mouse | LD50 | oral | > 2500mg/kg (2500mg/kg) | ? | Journal of Antibiotics. Vol. 28, Pg. 721, 1975. |
rat | LD50 | intraperitoneal | 18220ug/kg (18.22mg/kg) | ? | National Technical Information Service. Vol. PB83-228577, |
Carcinogenicity, Category 2
Reproductive toxicity, Category 2
Pictogram(s) | ![]() |
---|---|
Signal word | Danger |
Hazard statement(s) | H351 Suspected of causing cancer H361 Suspected of damaging fertility or the unborn child H372 Causes damage to organs through prolonged or repeated exposure |
Precautionary statement(s) | |
Prevention | P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/protective clothing/eye protection/face protection. |
Response | P308+P313 IF exposed or concerned: Get medical advice/ attention. |
Storage | P405 Store locked up. |
Disposal | P501 Dispose of contents/container to ... |
none
![]() |
![]() |
![]() |
As an mTOR inhibitor, sirolimus has a broad spectrum of activity that has demonstrated the ability to inhibit inflammation, proliferation, angiogenesis, fibrosis, and hyperpermeability. Sirolimus currently has multiple uses in the prevention of rejection in organ transplantation and, recently, in the treatment of advanced renal cell carcinoma. Sirolimus-eluting cardiac stents have been shown to limit the rate of overgrowth of tissue and thus prevent coronary restenosis. Early studies suggest that it may be an effective agent for controlling severe uveitis and that it may also have a role in treating agerelated macular degeneration.